Jefferies Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $29
Portfolio Pulse from richadhand@benzinga.com
Jefferies analyst Akash Tewari has initiated coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and a price target of $29.
August 08, 2023 | 9:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has initiated coverage on Apogee Therapeutics with a Buy rating and a price target of $29.
The initiation of coverage by Jefferies with a Buy rating indicates a positive outlook for Apogee Therapeutics. The price target of $29 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100